Literature DB >> 25232429

Sequential therapy versus standard triple therapy in Helicobacter pylori eradication in a high clarithromycin resistance setting.

Can Dolapcioglu1, Aysun Koc-Yesiltoprak2, Emel Ahishali1, Aziz Kural1, Hatice Dolapcioglu3, Aliye Soylu4, Resat Dabak2.   

Abstract

Sequential treatment scheme has been developed to overcome resistance problem in H. pylori eradication and favorable results have been obtained. This study compared the results of standard triple therapy with a sequential schema consisting of pantoprazole, amoxicillin, clarithromycin, and metronidazole in a high anti-microbial resistance setting. This retrospective study included subjects that underwent standard or sequential eradication treatment after a diagnosis of biopsy-documented H. pylori infection. Patients either received pantoprazole 40 mg bid, amoxicillin 1000 mg bid and clarithromycin 500 mg bid (PAC) for 10 days, or pantoprazole 40 mg bid and amoxicillin 1000 mg bid (PA) for the first 5 days of the treatment period and were then given pantoprazole 40 mg bid, clarithromycin 500 mg bid, and metronidazole 500 mg bid (PCM) in the remaining 5 days. Eradication was tested using urea breath test. The two treatment groups did not differ with regard to H. pylori eradication rate for both ITT population (63.9% versus 71.4% for standard and sequential therapy respectively, P = 0.278) and per protocol population (65.9% versus 74.1% for standard and sequential therapy respectively, P = 0.248). Although a sequential treatment appears to represent a plausible alternative, our findings suggest that alternative schedules may be required in certain populations to achieve higher success rates.

Entities:  

Keywords:  H. pylori; eradication; sequential therapy; standard therapy

Year:  2014        PMID: 25232429      PMCID: PMC4161589     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  19 in total

1.  Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report.

Authors:  Peter Malfertheiner; Francis Megraud; Colm A O'Morain; John Atherton; Anthony T R Axon; Franco Bazzoli; Gian Franco Gensini; Javier P Gisbert; David Y Graham; Theodore Rokkas; Emad M El-Omar; Ernst J Kuipers
Journal:  Gut       Date:  2012-05       Impact factor: 23.059

2.  Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults?

Authors:  Hyuk Yoon; Dong Ho Lee; Nayoung Kim; Young Soo Park; Cheol Min Shin; Kyu Keun Kang; Dong Hyun Oh; Dong Kee Jang; Jun-Won Chung
Journal:  J Gastroenterol Hepatol       Date:  2013-12       Impact factor: 4.029

3.  Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication.

Authors:  Xiao-Zhong Gao; Xiu-Li Qiao; Wen-Chong Song; Xiao-Feng Wang; Feng Liu
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

4.  Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: result of the HPFEZ randomised study.

Authors:  Mounia Lahbabi; Samia Alaoui; Karima El Rhazi; Mohammed El Abkari; Chakib Nejjari; Afaf Amarti; Bahia Bennani; Mustapha Mahmoud; Adil Ibrahimi; Dafr Allah Benajah
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-11-16       Impact factor: 2.947

5.  A new modified concomitant therapy for Helicobacter pylori eradication in Turkey.

Authors:  Ahmet Burak Toros; Ali Tüzün Ince; Besir Kesici; Mustafa Saglam; Zulfikar Polat; Ahmet Uygun
Journal:  Helicobacter       Date:  2011-06       Impact factor: 5.753

6.  Moxifloxacin-tetracycline-lansoprazole triple therapy for first-line treatment of Helicobacter pylori infection: a prospective study.

Authors:  Adnan Taş; Erdem Akbal; Erdem Koçak; Seyfettin Köklü
Journal:  Helicobacter       Date:  2011-02       Impact factor: 5.753

7.  Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.

Authors:  Jun-Won Chung; Young Kul Jung; Yoon Jae Kim; Kwang Ahn Kwon; Jung Ho Kim; Jong Joon Lee; Sung Min Lee; Ki Baik Hahm; Sun Mi Lee; Jin Yong Jeong; Sung-Cheol Yun
Journal:  J Gastroenterol Hepatol       Date:  2012-11       Impact factor: 4.029

8.  Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.

Authors:  V De Francesco; A Zullo; M Margiotta; S Marangi; O Burattini; P Berloco; F Russo; M Barone; A Di Leo; M F Minenna; V Stoppino; S Morini; C Panella; A Francavilla; E Ierardi
Journal:  Aliment Pharmacol Ther       Date:  2004-02-15       Impact factor: 8.171

9.  Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study.

Authors:  Hassan Seddik; Samir Ahid; Tarek El Adioui; Fatim-Zohra El Hamdi; Mohammed Hassar; Redouane Abouqal; Yahia Cherrah; Ahmed Benkirane
Journal:  Eur J Clin Pharmacol       Date:  2013-05-22       Impact factor: 2.953

10.  Sequential Therapy for Helicobacter pylori Infection in Korea: Systematic Review and Meta-Analysis.

Authors:  Joon Sung Kim; Byung-Wook Kim; Joo Ho Ham; Hyung Wook Park; Yun Kyeong Kim; Min Young Lee; Jeong-Seon Ji; Bo-In Lee; Hwang Choi
Journal:  Gut Liver       Date:  2013-08-14       Impact factor: 4.519

View more
  3 in total

1.  The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.

Authors:  Sebahat Basyigit; Ayse Kefeli; Ferdane Sapmaz; Abdullah Ozgür Yeniova; Zeliha Asilturk; Murat Hokkaomeroglu; Metin Uzman; Yasar Nazligul
Journal:  Bosn J Basic Med Sci       Date:  2015-10-25       Impact factor: 3.363

Review 2.  Treatment of Helicobacter pylori infection: Current and future insights.

Authors:  Maliheh Safavi; Reyhaneh Sabourian; Alireza Foroumadi
Journal:  World J Clin Cases       Date:  2016-01-16       Impact factor: 1.337

3.  The Development of Urease Inhibitors: What Opportunities Exist for Better Treatment of Helicobacter pylori Infection in Children?

Authors:  Sherif T S Hassan; Miroslava Šudomová
Journal:  Children (Basel)       Date:  2017-01-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.